TY - JOUR
T1 - Does Tumor Size Predict Response to Neoadjuvant Chemotherapy in the Modern Era of Biologically Driven Treatment? A Nationwide Study of US Breast Cancer Patients
AU - Livingston-Rosanoff, Devon
AU - Schumacher, Jessica
AU - Vande Walle, Kara
AU - Stankowski-Drengler, Trista
AU - Greenberg, Caprice C.
AU - Neuman, Heather
AU - Wilke, Lee G.
N1 - Funding Information:
The NCDB is a joint project of the American College of Surgeons Commission on Cancer and the American Cancer Society. The hospitals participating in the NCDB are the source of the deidentified data used herein; they have not verified and are not responsible for the statistical validity of the data analysis of the conclusions derived by the authors. This work was supported by the National Institutes of Health (T32 CA090217 to D.L.-R. T.S.-D. and K.V.W.) and American College of Surgeons (Resident Research Scholarship to D.L.-R.).
Funding Information:
The NCDB is a joint project of the American College of Surgeons Commission on Cancer and the American Cancer Society. The hospitals participating in the NCDB are the source of the deidentified data used herein; they have not verified and are not responsible for the statistical validity of the data analysis of the conclusions derived by the authors. This work was supported by the National Institutes of Health ( T32 CA090217 to D.L.-R., T.S.-D., and K.V.W.) and American College of Surgeons (Resident Research Scholarship to D.L.-R.).
Publisher Copyright:
© 2019 Elsevier Inc.
PY - 2019/12
Y1 - 2019/12
N2 - Background: Tumor size has historically been used to stage breast cancer and guide treatment recommendations. The importance of tumor biology in long-term outcomes is increasingly being acknowledged. No large studies have examined the relative roles of tumor size and receptor status on response to neoadjuvant chemotherapy (NAC) in breast cancer. Patients and Methods: The National Cancer Database was queried for women who underwent NAC and surgery for unilateral clinical stage I to III (cT1-3) invasive breast cancer from 2010 to 2013. Multivariable logistic regression models were used to assess the relation between receptor status, tumor size, and pathologic complete response (pCR) while controlling for other biologic, sociodemographic, diagnosis, and treatment factors. Results: We included 38,864 women in this study, most presented with cT2 disease (55%). Patients predominantly had estrogen receptor (ER)/progesterone receptor (PR)-positive (ER/PR+) HER2− (45%) or ER/PR− HER2− (28%) disease. Nineteen percent (7432 patients) had a pCR. cT3 (odds ratio [OR], 0.64; 95% confidence interval [CI], 0.59-0.70) but not cT2 cancers (OR, 0.95; 95% CI, 0.89-1.02) were associated with lower pCR rates compared with cT1 disease. HER2+ (ER/PR+ HER2+: OR, 2.94; 95% CI, 2.72-3.18; ER/PR− HER2+: OR, 6.45; 95% CI, 5.92-7.02) and ER/PR− HER2− cancers (OR, 3.94; 95% CI, 3.68-4.22) were more likely to experience pCR than those with ER/PR+ HER2− cancers. Receptor status was more strongly associated with pCR than tumor size. Conclusion: Tumor size is independently associated with pCR after NAC after controlling for receptor status, although the effect of receptor status is stronger. These data reinforce the importance of receptor status as well as tumor size, each of which might act as surrogates for tumor biology, in setting expectations for outcomes in patients who undergo NAC.
AB - Background: Tumor size has historically been used to stage breast cancer and guide treatment recommendations. The importance of tumor biology in long-term outcomes is increasingly being acknowledged. No large studies have examined the relative roles of tumor size and receptor status on response to neoadjuvant chemotherapy (NAC) in breast cancer. Patients and Methods: The National Cancer Database was queried for women who underwent NAC and surgery for unilateral clinical stage I to III (cT1-3) invasive breast cancer from 2010 to 2013. Multivariable logistic regression models were used to assess the relation between receptor status, tumor size, and pathologic complete response (pCR) while controlling for other biologic, sociodemographic, diagnosis, and treatment factors. Results: We included 38,864 women in this study, most presented with cT2 disease (55%). Patients predominantly had estrogen receptor (ER)/progesterone receptor (PR)-positive (ER/PR+) HER2− (45%) or ER/PR− HER2− (28%) disease. Nineteen percent (7432 patients) had a pCR. cT3 (odds ratio [OR], 0.64; 95% confidence interval [CI], 0.59-0.70) but not cT2 cancers (OR, 0.95; 95% CI, 0.89-1.02) were associated with lower pCR rates compared with cT1 disease. HER2+ (ER/PR+ HER2+: OR, 2.94; 95% CI, 2.72-3.18; ER/PR− HER2+: OR, 6.45; 95% CI, 5.92-7.02) and ER/PR− HER2− cancers (OR, 3.94; 95% CI, 3.68-4.22) were more likely to experience pCR than those with ER/PR+ HER2− cancers. Receptor status was more strongly associated with pCR than tumor size. Conclusion: Tumor size is independently associated with pCR after NAC after controlling for receptor status, although the effect of receptor status is stronger. These data reinforce the importance of receptor status as well as tumor size, each of which might act as surrogates for tumor biology, in setting expectations for outcomes in patients who undergo NAC.
KW - Complete pathologic response
KW - NAC
KW - NCDB
KW - National Cancer Database
KW - TNM staging
UR - http://www.scopus.com/inward/record.url?scp=85068456011&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85068456011&partnerID=8YFLogxK
U2 - 10.1016/j.clbc.2019.05.014
DO - 10.1016/j.clbc.2019.05.014
M3 - Article
C2 - 31300338
AN - SCOPUS:85068456011
SN - 1526-8209
VL - 19
SP - e741-e747
JO - Clinical Breast Cancer
JF - Clinical Breast Cancer
IS - 6
ER -
